Since vascular endothelial growth factor (VEGF) is a predominant proangiogenic factor in CNV, wet AMD can be treated with intravitreous administration of anti-angiogenic agents such as aflibercept and ranibizumab (Supuran, 2019). The gene discussed is VEGFA; the disease is wet macular degeneration.